The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia

被引:2
|
作者
Mu, Lin [1 ]
Miao, Jing-Rui [1 ]
Song, Jing-Hui [1 ]
机构
[1] Inner Mongolia Med Univ, Dept Obstet & Gynecol, Affiliated Hosp, 1 North Tongdao St, Inner Mongolia 100059, Peoples R China
基金
中国国家自然科学基金;
关键词
Cervical intraepithelial neoplasia (CIN); cervical squamous cell carcinoma; HPV; 16; 18; vaginal local immune factor; PROGRESSION; DNA;
D O I
10.21037/tcr-19-2955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aimed to investigate the correlation between the level of HPV16 and HPV18 in patients with cervical lesions and the local vaginal immunity after receiving treatment with different degrees of cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma (CSCC). Methods: One hundred and thirty-six patients with LSIL (grade 1 CIN or CIN 1), 263 patients with HSIL (grade 2 and 3 CIN or CIN 2 and 3), and 33 patients with CSCC pathologically confirmed between November 2012 and September 2016 were assigned to the test group and 100 healthy women in the same period were assigned to the control group. ELISA was used to determine the levels of SIgA, IgG, IL-2, and IL-10 and the IL-2/IL-10 ratio in vaginal lavage fluid in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Gene chip technology was adopted to test the HPV infection in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Results: The results showed that the levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in all patients before treatment. The levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in HPV16 and HPV18-infected patients before receiving the treatment. Conclusions: The recovery after the treatment of HPV infection is time-dependent and the immune system of patients with CIN starts to recover in the 6th month after treatment, early intervention is not recommended. However, the immune system is approximately in a normal sate at 12 months after treatment, at which time the efficacy can be evaluated, and clinical intervention can be initiated if necessary. The level of local immune factors in the vagina can be monitored to determine the progression and prognosis of patients' cervical lesions.
引用
收藏
页码:4212 / 4223
页数:12
相关论文
共 50 条
  • [21] 应用PCR技术检测肺癌组织中HPV16、HPV18
    宋长芹
    孙洪涛
    周大铮
    李超
    预防医学论坛, 1997, (04) : 387 - 388
  • [22] QUANTITATIVE ORAL HPV16 AND HPV18 DETECTION IN PATIENTS ATTENDING DENTAL CLINICS
    Stankiewicz, Helen
    Magaret, Amalia
    Feng, Quinne
    Wald, Anna
    SEXUALLY TRANSMITTED INFECTIONS, 2019, 95 : A351 - A351
  • [23] WarmStart colorimetric LAMP for the specific and rapid detection of HPV16 and HPV18 DNA
    Daskou, M.
    Tsakogiannis, D.
    Dimitriou, T. G.
    Amoutzias, G. D.
    Mossialos, D.
    Kottaridi, C.
    Gartzonika, C.
    Markoulatos, P.
    JOURNAL OF VIROLOGICAL METHODS, 2019, 270 : 87 - 94
  • [24] The efficacy of bivalent and tetravalent HPV vaccination against cervical intraepithelial neoplasia and persistent HPV 16 and 18 infection
    Riaz, H.
    Denyer, M.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 : 176 - 177
  • [25] Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program
    Onuki, Mamiko
    Yamamoto, Kasumi
    Yahata, Hideaki
    Kanao, Hiroyuki
    Horie, Koji
    Konnai, Katsuyuki
    Nio, Ai
    Takehara, Kazuhiro
    Kamiura, Shoji
    Tsuda, Naotake
    Takei, Yuji
    Shigeta, Shogo
    Nakai, Hidekatsu
    Yoshida, Hiroyuki
    Motohara, Takeshi
    Kato, Tatsuya
    Nakamura, Keiichiro
    Hamanishi, Junzo
    Tasaka, Nobutaka
    Ishikawa, Mitsuya
    Kado, Nobuhiro
    Taira, Yusuke
    Mori, Mayuyo
    Iwata, Takashi
    Takahashi, Fumiaki
    Kukimoto, Iwao
    Yoshikawa, Hiroyuki
    Yaegashi, Nobuo
    Matsumoto, Koji
    VACCINES, 2022, 10 (02)
  • [26] Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women
    Zhao, Junwei
    Zhu, Jiacheng
    Guo, Junhan
    Zhu, Tailin
    Zhong, Jixing
    Liu, Min
    Ruan, Yetian
    Liao, Shujie
    Li, Fang
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (03) : 372 - 381
  • [27] HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3
    Baandrup, L.
    Munk, C.
    Andersen, K. K.
    Junge, J.
    Iftner, T.
    Kjaer, S. K.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (02) : 281 - 285
  • [28] Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia
    Mirabello, Lisa
    Schiffman, Mark
    Ghosh, Arpita
    Rodriguez, Ana C.
    Vasiljevic, Natasa
    Wentzensen, Nicolas
    Herrero, Rolando
    Hildesheim, Allan
    Wacholder, Sholom
    Scibior-Bentkowska, Dorota
    Burk, Robert D.
    Lorincz, Attila T.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (06) : 1412 - 1422
  • [29] ROLE OF CYTOLOGY AND HPV TESTING AFTER TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA
    Andonova, I.
    Iliev, N.
    Zivkovic, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [30] HPV vaccination after treatment of cervical intraepithelial neoplasia (CIN/HSIL)
    Dannecker, Christian
    GYNAKOLOGE, 2021, 54 (11): : 816 - 819